Life Sciences Tools and Services
Company Overview of The EMMES Corporation
The EMMES Corporation operates as a contract research organization. Its products include EMMES AdvantageEDC, a platform that provides study design tools and data collection in electronic case report forms and data quality management; EMMES RTS, a platform to assist in coordination, collection, organization, and retrieval of regulatory documentation for investigational sites; and EMMES GlobalTrace, a materials/specimen management platform that tracks in real-time from collection at a clinical site to arrival and storage at a central laboratory or repository. The company’s services include statistical leadership and project management, study design and protocol development, Web-based data coll...
401 North Washington Street
Rockville, MD 20850
Founded in 1977
Key Executives for The EMMES Corporation
Chief Executive Officer and President
Chief Financial Officer and Vice President
Compensation as of Fiscal Year 2017.
The EMMES Corporation Key Developments
Emmes Corp Wins $69.72 Million Federal Contract
Aug 3 17
Emmes Corp. won a $69,717,369.27 federal contract from the U.S. Department of Health and Human Services National Institutes of Health for support services for Best Pharmaceuticals for Children Act Data Coordinating Center.
The Emmes Corporation Opens New Office in Frederick, MD
Jun 29 17
The Emmes Corporation announced that it has expanded its operations in greater Washington to include a new office in Frederick, Maryland. The company's decision to open an office in Frederick incorporated feedback from some employees on the length of their commute to the Rockville headquarters. Instead of expanding office space in Rockville, the company decided to seek additional space in Frederick and offered its Rockville staff the opportunity to choose where to wor k.
The Emmes Corporation Expands Zika Vaccine Research Contract
May 3 17
The Emmes Corporation announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. The clinical study is being conducted for the National Institute of Allergy and Infectious Disease'sVaccine Research Center at the National Institutes of Health (NIH). The study, titled a Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents, is being conducted in two parts. Under the contract, the company will lead the data management, statistical, regulatory, and clinical monitoring efforts. The company currently supports the predecessor study, a Phase 1 trial that is testing the same Zika vaccine in 45 subjects. In addition to the Zika studies for the Vaccine Research Center, Emmes supports four other Zika clinical trials.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|